Alvotech (ALVO) Competitors $8.43 -0.01 (-0.12%) As of 09:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVO vs. VTRS, BBIO, VRNA, BPMC, ROIV, GRFS, LEGN, ELAN, RVMD, and RYTMShould you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Viatris (VTRS), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Alvotech vs. Its Competitors Viatris BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Grifols Legend Biotech Elanco Animal Health Revolution Medicines Rhythm Pharmaceuticals Alvotech (NASDAQ:ALVO) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation. Do analysts prefer ALVO or VTRS? Alvotech presently has a consensus price target of $14.00, indicating a potential upside of 66.07%. Viatris has a consensus price target of $10.40, indicating a potential upside of 10.82%. Given Alvotech's stronger consensus rating and higher possible upside, equities analysts plainly believe Alvotech is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alvotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Which has stronger valuation & earnings, ALVO or VTRS? Alvotech has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlvotech$585.60M4.34-$231.86M$0.3722.78Viatris$14.74B0.75-$634.20M-$3.17-2.96 Do insiders and institutionals have more ownership in ALVO or VTRS? 79.9% of Viatris shares are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 0.1% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is ALVO or VTRS more profitable? Alvotech has a net margin of 16.42% compared to Viatris' net margin of -26.45%. Viatris' return on equity of 16.20% beat Alvotech's return on equity.Company Net Margins Return on Equity Return on Assets Alvotech16.42% -36.37% 12.70% Viatris -26.45%16.20%7.01% Does the media prefer ALVO or VTRS? In the previous week, Viatris had 9 more articles in the media than Alvotech. MarketBeat recorded 13 mentions for Viatris and 4 mentions for Alvotech. Viatris' average media sentiment score of 0.29 beat Alvotech's score of 0.00 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, ALVO or VTRS? Alvotech has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. SummaryAlvotech beats Viatris on 9 of the 15 factors compared between the two stocks. Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVO vs. The Competition Export to ExcelMetricAlvotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.54B$2.98B$5.42B$9.56BDividend YieldN/A2.46%3.99%4.14%P/E Ratio22.7817.9729.9025.14Price / Sales4.34177.57372.1776.15Price / CashN/A41.8335.9458.58Price / Book-6.157.238.105.59Net Income-$231.86M-$54.43M$3.26B$265.48M7 Day Performance-4.10%0.22%0.65%1.22%1 Month Performance-4.31%5.59%2.43%0.39%1 Year Performance-22.66%9.98%27.70%23.47% Alvotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVOAlvotech2.8588 of 5 stars$8.43-0.1%$14.00+66.1%-23.3%$2.54B$585.60M22.781,032VTRSViatris2.6727 of 5 stars$8.94+1.5%$10.40+16.3%-17.3%$10.34B$14.74B-2.8232,000News CoverageEarnings ReportDividend AnnouncementShort Interest ↑Gap UpBBIOBridgeBio Pharma4.7221 of 5 stars$47.75+0.8%$61.18+28.1%+92.1%$8.99B$221.90M-13.53400News CoverageEarnings ReportAnalyst ForecastInsider TradeOptions VolumeAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share1.8765 of 5 stars$105.47+0.3%$109.00+3.3%+439.7%$8.95B$42.28M-52.7430Positive NewsEarnings ReportInsider TradeBPMCBlueprint Medicines0.688 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences2.3632 of 5 stars$11.51+1.8%$16.50+43.4%+13.6%$7.69B$29.05M-46.04860Positive NewsUpcoming EarningsGRFSGrifols3.2083 of 5 stars$10.72-0.6%$10.30-3.9%+43.3%$7.41B$7.81B9.1623,822Analyst ForecastLEGNLegend Biotech3.8484 of 5 stars$38.45-0.9%$73.33+90.7%-32.0%$7.13B$627.24M-65.172,609News CoveragePositive NewsUpcoming EarningsAnalyst RevisionELANElanco Animal Health3.3481 of 5 stars$14.07+2.1%$16.17+14.9%+32.4%$6.85B$4.44B19.029,000Trending NewsEarnings ReportRVMDRevolution Medicines4.4459 of 5 stars$37.18+1.5%$68.91+85.3%-17.3%$6.82B$11.58M-9.30250News CoverageEarnings ReportAnalyst ForecastGap DownRYTMRhythm Pharmaceuticals3.5671 of 5 stars$90.24+2.2%$91.93+1.9%+112.3%$5.62B$130.13M-32.11140Earnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies VTRS Competitors BBIO Competitors VRNA Competitors BPMC Competitors ROIV Competitors GRFS Competitors LEGN Competitors ELAN Competitors RVMD Competitors RYTM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVO) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alvotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Alvotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALVO Stock Alerts